Adjuvant vemurafenib in resected, BRAFV600 mutation-positive melanoma (BRIM8): a randomised, double-blind, placebo-controlled, multicentre, phase 3 trial

BRIM8 Investigators

Research output: Contribution to journalArticlepeer-review

Fingerprint

Dive into the research topics of 'Adjuvant vemurafenib in resected, BRAFV600 mutation-positive melanoma (BRIM8): a randomised, double-blind, placebo-controlled, multicentre, phase 3 trial'. Together they form a unique fingerprint.

Medicine & Life Sciences